France’s Pharmaceutical Market Value Will Crawl to $48.2 Billion by 2020 as Generics Limit Growth, says GlobalData
				
							
								
					
				
							
								
					
				
					
						
		| 04 Février 2015
The company’s latest report*  states that France was a relatively late entrant to the generics market  compared to the UK and Germany. In 2008, generic drugs accounted for  21.7% of the pharmaceutical market in terms of volume, which increased  to 30.2% in 2013. Joshua Owide, GlobalData’s  Director of Healthcare Industry Dynamics, says that the French  government is promoting generics as a measure to reduce healthcare  expenditure. In September 2012, it introduced a scheme under which  patients who agree to generic substitution will not be required to pay  for their drugs. Owide explains: “While patented  drugs dominate France’s pharmaceutical market, the volume of  prescribing attributed to generic drugs will shift closer to levels seen  in the rest of Europe, restricting French market growth. “The generic sector is mainly  driven by a favorable regulatory regime, patent expirations and a  variety of government incentives for physicians, pharmacists and  patients to choose generics ahead of branded products.” Despite the negative impact of  generics, France’s pharmaceutical market will be boosted by a number of  factors, including an aging population, tax incentives, a substantial  skilled workforce and high public healthcare expenditure. Owide comments: “By 2020,  France’s elderly population is expected to account for almost 20% of the  total population. As this demographic demands more medication than  younger demographics, the need for high-quality healthcare is  increasing. “Additionally, numerous  incentives, such as the abolition of corporate tax and the Research Tax  Credit to support research and development, are enhancing the  competitiveness of healthcare enterprises and will help to sustain the  pharmaceutical market.”
LONDON, UK (GlobalData), 3  February 2015 - The French pharmaceutical market is forecast to grow at a  tepid Compound Annual Growth Rate (CAGR) of 0.7% from $46.2 billion in  2014 to $48.2 billion by 2020, restricted by an increasing focus on  generic drugs, according to research and consulting firm GlobalData.






